Journal article
Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study1
Abstract
To assess the effects of troglitazone monotherapy on glycemic control in patients with type 2 diabetes mellitus, we carried out a 6-month, randomized, double-blind, placebo-controlled study in 24 hospital and outpatient clinics in the United States and Canada. Troglitazone 100, 200, 400, or 600 mg or placebo once daily with breakfast was administered to 402 patients with type 2 diabetes with fasting serum glucose (FSG) > 140 mg/dL, glycosylated …
Authors
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
Journal
The Journal of Clinical Endocrinology & Metabolism, Vol. 83, No. 9, pp. 3169–3176
Publisher
The Endocrine Society
Publication Date
September 1998
DOI
10.1210/jcem.83.9.5123
ISSN
0021-972X